The following is a summary of “Exploring itch in hidradenitis suppurativa with lessons from atopic dermatitis and psoriasis,” ...

Patients with Hidradenitis Suppurativa (HS) are at a significantly higher risk of obstructive sleep apnea (OSA) compared to ...

Adults with hidradenitis suppurativa were at a greater risk for noninfectious uveitis than control individuals, which ...

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...

MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies in mid-2025. Click here ...

Panelist discusses how delayed medical diagnosis causes significant economic burden through increased treatment costs, prolonged health care interventions, reduced patient productivity, and higher ...

Living with a skin condition like hidradenitis suppurativa (HS) or folliculitis can be challenging, especially when you’re not sure what’s causing your symptoms. Both of these conditions cause ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients ...

Hidradenitis suppurativa is more common among patients with Crohn disease (CD) than ulcerative colitis (UC), yet bowel obstruction affects both CD and UC.

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

Goldman Sachs analyst Richard Law upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral with a price target of $82, up from $62. The ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis ...